Potential CRISPR Treatments for Bronchiectasis & NTM

​In May, a Bronchiectasis and NTM patient conference was held in Berkeley, California. At that conference, there was an inspiring discussion about CRISPR technology — ​

--the revolutionary gene‑editing tool that earned Drs. Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry.

And, coincidentally, Dr. Doudna’s academic home is right there in Berkeley, at the University of California — the very place where some of the world’s most exciting CRISPR research is unfolding.

So what does this have to do with bronchiectasis and MAC? Researchers are now exploring ways to harness CRISPR’s power to improve both treatment and diagnosis for people living with these challenging lung conditions.

---

CRISPR as a future treatment for bronchiectasis

Researchers are investigating whether CRISPR gene editing could one day correct the underlying cellular or genetic mechanisms that drive bronchiectasis progression. For example:

• Repairing or replacing faulty genes that impair mucociliary clearance or weaken immune defenses.
  
  
• Suppressing overactive inflammatory pathways at the DNA level to prevent ongoing lung damage.
  
  
• Targeting specific bacteria within the lungs to eliminate chronic infection — without harming healthy bacteria.
  
  

While this work is still experimental, it opens the door to the idea of disease‑modifying therapies, not just symptom management.

---

CRISPR as a Diagnostic Tool for MAC Infections

MAC (Mycobacterium avium complex) a stubborn cause of lung infections in bronchiectasis. Detecting MAC quickly and accurately is critical — yet current tests like sputum culture can take weeks, and many of us with “dry bronchiectasis” struggle to produce a sputum sample in the first place.

Here’s where CRISPR‑based diagnostics come in:

• Researchers have developed CRISPR‑Cas systems that can be programmed to detect genetic material in the blood unique to MAC.
  
  
• These tests could deliver results in minutes to hours — and be more sensitive and specific than traditional methods.

​
Faster results mean earlier treatment and less waiting, which can make a real difference for people managing chronic infections.

---

Final thoughts

CRISPR is still in its early days as it relates to bronchiectasis and MAC, but its potential is inspiring. From faster, more accurate diagnostics to the possibility of actually repairing or preventing airway damage at the genetic level, this technology could reshape what it means to live with chronic lung disease.

For now, staying informed about advances like these, and working closely with your care team, is one of the best ways to prepare for the future of bronchiectasis care. Science is moving forward, and so are we.